Stock comparison
Genmab A/S
MiMedx Group
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
MDXG
MiMedx Group
Market cap
$539.18M
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | MDXG | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 57C | GMAB |
| Benjamin Graham | 64C | 50D | GMAB |
| Philip Fisher | 48D | 54C | MDXG |
| Peter Lynch | 25F | 48D | MDXG |
| Joel Greenblatt | 76B | 22F | GMAB |
| Charlie Munger | 68C | 44D | GMAB |
| Terry Smith | 71C | 51D | GMAB |
Side-by-side metrics
| Metric | GMAB | MDXG |
|---|---|---|
| Market cap | $16.5B | $539.18M |
| P/E (TTM) | 6.2x | 17.6x |
| EV/EBIT | 12.0x | 6.0x |
| ROIC (TTM) | 43.78% | 10.81% |
| Gross margin | 93.88% | 81.04% |
| Net margin | 18.23% | 7.88% |
| Revenue CAGR 5y | -18.45% | 14.68% |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Market cap$16.5Bvs $539.18M+97%
- ROIC (TTM)43.78%vs 10.81%+75%
- P/E (TTM)6.2xvs 17.6x+65%
- Net margin18.23%vs 7.88%+57%
MDXG leads on
- Revenue CAGR 5y14.68%vs -18.45%+180%
- Debt / Equity0.0xvs 0.1x+92%
- EV/EBIT6.0xvs 12.0x+50%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.